Our Pricing

Mounjaro Discount Codes For Existing Customers at Cured Pharmacy

Published on: June 03, 2026

Searching for mounjaro discount codes existing customers uk can be frustrating when many pharmacies hide their pricing or reserve discounts for new patients only. At Cured Pharmacy, we believe in transparent upfront pricing for all patients — whether you're starting Mounjaro for the first time or continuing your weight loss journey. Our Mounjaro pens start from £124.99 with no consultation fees and the same competitive pricing for every prescription.

Understanding Mounjaro Discount Codes For Existing Customers

Many UK online pharmacies advertise promotional codes that apply only to first orders, leaving existing customers paying significantly higher prices for repeat prescriptions. This practice creates confusion and financial strain for patients who require long-term treatment. At Cured Pharmacy, we've eliminated this two-tier pricing structure entirely — our prices remain consistent whether you're ordering your first pen or your twelfth.

Mounjaro (tirzepatide) is a prescription-only medication that typically requires ongoing treatment for optimal results. Clinical trials demonstrate that sustained weight loss occurs over 52 to 72 weeks of continuous use [1]. Transparent pricing for existing customers isn't just fair — it's essential for patients who need to budget for extended treatment courses.

Rather than offering temporary discount codes that expire after one use, we focus on maintaining the lowest baseline prices in the UK market. This approach means you won't need to search for promotional codes before each refill or worry about sudden price increases when your 'new customer' status expires.

How Mounjaro Works: The Science Behind Tirzepatide

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. This dual mechanism enhances insulin secretion, reduces glucagon levels, slows gastric emptying, and significantly reduces appetite.

In the landmark SURPASS-3 trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks — substantially higher than results observed with single-pathway alternatives [1][2]. The SURMOUNT-1 trial further demonstrated that adults without diabetes achieved up to 20.9% weight reduction at the highest dose [3].

The medication is administered via a pre-filled KwikPen once weekly. Dosing begins at 2.5mg for the first four weeks to minimise gastrointestinal side effects, then escalates gradually to a maintenance dose between 5mg and 15mg based on individual response and tolerability. All dose adjustments must be supervised by a UK-registered prescriber.

Clinical Efficacy in Real-World Settings

Beyond controlled trial environments, real-world evidence from UK patients demonstrates that tirzepatide maintains its efficacy when used as part of a comprehensive weight management programme. Patients who combine Mounjaro with dietary modifications and increased physical activity typically experience better outcomes than those relying on medication alone [4]. Your prescriber will provide personalised guidance on lifestyle factors that optimise treatment response.

Transparent Pricing Structure at Cured Pharmacy

At Cured Pharmacy, Mounjaro starts from £124.99 per pen, with final pricing determined by your prescribed dose. This price includes the medication, clinical assessment, and discreet UK delivery — no hidden consultation fees or administrative charges. We display prices before you begin your consultation, allowing you to make informed decisions about your treatment.

Our pricing remains consistent for all patients. You won't encounter promotional codes that only apply to first orders, nor will you see your costs increase once you're classified as an existing customer. This transparent approach eliminates the need to search for discount codes before each refill or switch pharmacies to access better rates.

All prescription medications at Cured Pharmacy require a clinical assessment by a UK-registered prescriber. Our online consultation takes under three minutes and is completely free. If Mounjaro isn't suitable based on your medical history, our clinical team will recommend alternative treatments from our weight loss range without any consultation charges.

Price Comparison: What You're Actually Paying For

When comparing Mounjaro prices across UK pharmacies, it's essential to account for all costs. Some providers advertise lower medication prices but charge separately for consultations, prescription reviews, or delivery. At Cured Pharmacy, our quoted price covers everything — there are no surprise fees at checkout. We're registered with the General Pharmaceutical Council (GPhC Registration Number 9012511), and our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets UK regulatory standards.

Mounjaro vs Alternative Weight Loss Treatments

The UK market offers several prescription weight loss treatments, each with distinct mechanisms, dosing schedules, and efficacy profiles. Understanding these differences helps you and your prescriber select the most appropriate option for your circumstances.

Wegovy (semaglutide) is a single GLP-1 receptor agonist administered once weekly via injection. In the STEP-1 trial, participants achieved an average weight reduction of 14.9% over 68 weeks [2]. Whilst this represents significant clinical benefit, head-to-head comparisons suggest tirzepatide produces greater weight loss in most patients due to its dual receptor mechanism [5].

Saxenda (liraglutide) is an older GLP-1 treatment requiring daily injections rather than weekly administration. Clinical trials showed an average weight loss of 8% over 56 weeks [6]. The daily injection schedule can be less convenient for patients with busy lifestyles, though some individuals prefer more frequent dosing for better appetite control throughout the day.

Oral medications like Orlistat work through a completely different mechanism — blocking fat absorption in the digestive system rather than affecting appetite hormones. Orlistat typically produces more modest weight loss (around 5-10% of body weight) and requires strict adherence to a low-fat diet to minimise gastrointestinal side effects [7]. It may be appropriate for patients who prefer oral medication or have contraindications to injectable treatments.

Eligibility Criteria and Clinical Assessment Process

Mounjaro is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. These criteria align with NICE guidelines for prescribing weight management medications [8].

Our online consultation collects essential medical information including current medications, existing health conditions, previous weight loss attempts, and any contraindications to GLP-1 therapy. A UK-registered prescriber reviews every submission individually — this isn't an automated approval system. If Mounjaro isn't clinically appropriate, our team will explain why and suggest suitable alternatives from our weight loss range.

Certain medical conditions preclude Mounjaro use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic ketoacidosis. Women who are pregnant, breastfeeding, or planning pregnancy should not use tirzepatide. Your prescriber will assess all risk factors before approving treatment.

Ongoing Monitoring and Prescription Renewals

Weight loss medications require regular monitoring to assess efficacy, tolerability, and any emerging safety concerns. UK prescribing guidelines recommend reviewing treatment every 12 weeks, with dose adjustments based on weight loss progress and side effect profile. At Cured Pharmacy, repeat prescriptions undergo the same clinical review process as initial orders — we never auto-renew prescriptions without prescriber approval. This ensures your treatment remains appropriate as your health status evolves.

Managing Side Effects and Optimising Treatment Outcomes

The most common side effects of Mounjaro are gastrointestinal: nausea, diarrhoea, vomiting, constipation, and abdominal discomfort. These symptoms typically occur during dose escalation phases and diminish as your body adapts to the medication [1]. Starting at the lowest dose (2.5mg) and increasing gradually every four weeks minimises these effects.

To reduce nausea, eat smaller, more frequent meals rather than large portions. Avoid high-fat, spicy, or heavily processed foods, particularly during the first few weeks of treatment. Stay well-hydrated, and consider taking your injection in the evening so peak medication levels occur during sleep when nausea is less noticeable.

Rare but serious side effects include pancreatitis (severe abdominal pain radiating to the back), gallbladder problems, kidney injury from dehydration, and hypoglycaemia in patients taking other diabetes medications. Contact your GP or NHS 111 immediately if you experience severe abdominal pain, persistent vomiting, signs of dehydration, or unexplained visual changes. Always inform your prescriber about any side effects during follow-up consultations.

Maximum weight loss typically occurs between 52 and 72 weeks of continuous treatment [3]. Patients who discontinue Mounjaro often experience weight regain, highlighting the importance of establishing sustainable lifestyle changes during treatment. Your prescriber will discuss long-term weight maintenance strategies as you approach your goal weight.

When to Contact Your Healthcare Provider

Seek immediate medical attention if you develop severe abdominal pain, persistent vomiting that prevents you from keeping down fluids, signs of an allergic reaction (rash, swelling, difficulty breathing), or sudden vision changes. For non-urgent concerns about side effects or treatment efficacy, contact our clinical team through your Cured Pharmacy account. We provide ongoing support throughout your treatment journey, not just at the point of prescription.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Garvey, W. T., et al. (2023). Tirzepatide Once Weekly for the Treatment of Obesity in People without Diabetes (SURMOUNT-1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 402(10402), 580–591. https://doi.org/10.1016/S0140-6736(23)01200-X [accessed 13 August 2026]
4. Ryan, D. H., & Yockey, S. R. (2017). Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Current Obesity Reports, 6(2), 187–194. https://doi.org/10.1007/s13679-017-0262-y [accessed 13 August 2026]
5. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398(10295), 64–77. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
6. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
7. Torgerson, J. S., et al. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
8. National Institute for Health and Care Excellence. (2023). Obesity: Identification, Assessment and Management (Clinical Guideline CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.